Latest Wearable Sensors News

dorsaVi has completed the design of its first integrated RRAM-CMOS validation chip, featuring self-checking write-and-verify, compute-in-memory capabilities, and scalable integration on commercial CMOS wafers. The milestone sets the stage for fabrication and commercial engagement in high-value edge AI markets.

Alterity Therapeutics has clinched FDA agreement on the pivotal Phase 3 trial design for ATH434, targeting Multiple System Atrophy, with the trial set to begin by the end of 2026.

Alterity Therapeutics has showcased compelling Phase 2 data for ATH434 in Multiple System Atrophy, paving the way for a Phase 3 trial with FDA engagement targeted for mid-2026.

dorsaVi has secured a 12-month renewal of its Department of Defense-funded research with Georgia Southern University, advancing real-time gait optimisation to reduce military training injuries and laying groundwork for its exoskeleton and neuromorphic computing strategy.

dorsaVi has initiated its Ultra-Edge Modular Design program, transitioning from IP development to a manufacturable hardware platform targeting robotics, exoskeletons, and industrial AI with ultra-low power consumption.

dorsaVi has launched a multi-year partnership with Taiwan’s ITRI and NTU to develop its proprietary RRAM platform at the 22-nm node, complemented by a new advisory board and neuromorphic IP acquisition, positioning the company at the forefront of ultra-edge AI hardware.

dorsaVi is pivoting from wearable sensors to powering next-gen exoskeletons, leveraging its neuromorphic RRAM technology to tap a projected $2 billion market by 2033.

dorsaVi has confirmed that its proprietary RRAM memory technology and neuromorphic IP portfolio work seamlessly together, projecting a tenfold boost in performance for robotics and exoskeleton applications. This breakthrough lays the groundwork for smarter, faster, and more energy-efficient wearable and robotic devices operating at the ultra-edge.

dorsaVi has commenced development of Sensor V6.5, a firmware upgrade that embeds intelligence directly within its wearable sensors, reducing latency and paving the way for future neuromorphic computing integration.

dorsaVi has secured significant commercial and clinical milestones with new elite sports and European clinical partnerships, showcasing its advanced real-time AI sensor technology.

dorsaVi reports strong US commercial growth with over 100 new physical therapy sites and a 50% rise in cash receipts, alongside a strategic leadership change and breakthrough neuromorphic technology acquisition.

dorsaVi Limited has acquired a cutting-edge neuromorphic processing-in-memory technology portfolio, positioning itself at the forefront of next-generation wearable and robotics intelligence. This strategic move, coupled with leadership changes, signals a new era for the company’s adaptive biosensor and robotics platforms.